Income Statement Resverlogix Corp. OTC Markets
Stocks
RVXCF
CA76128M1086
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0752 USD | +7.05% |
|
+8.36% | +1.35% |
| 06-25 | Resverlogix Corp. - Shareholder/Analyst Call | |
| 05-15 | Resverlogix Corp. Reports Earnings Results for the First Quarter Ended March 31, 2026 | CI |
| Fiscal Period: December | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Selling General & Admin Expenses, Total | 11.39M | 7.2M | 3.02M | 1.8M | 1.96M | |||||
R&D Expenses | 4.55M | 4.23M | 2.16M | 2.8M | 2.95M | |||||
Other Operating Expenses, Total | 15.94M | 11.43M | 5.18M | 4.6M | 4.91M | |||||
Operating Income | -15.94M | -11.43M | -5.18M | -4.6M | -4.91M | |||||
Interest Expense, Total | -700K | -1.64M | -1.81M | -3.12M | -4.2M | |||||
Net Interest Expenses | -700K | -1.64M | -1.81M | -3.12M | -4.2M | |||||
Currency Exchange Gains (Loss) | -81K | 29K | -19K | 51K | -45K | |||||
Other Non Operating Income (Expenses) | 4.73M | 3.36M | 721K | 564K | -110K | |||||
EBT, Excl. Unusual Items | -11.99M | -9.68M | -6.28M | -7.1M | -9.26M | |||||
Asset Writedown | - | -1.28M | -1.03M | - | -155K | |||||
Other Unusual Items | -12.77M | 7.37M | -9.41M | -520K | 1.66M | |||||
EBT, Incl. Unusual Items | -24.76M | -3.59M | -16.73M | -7.62M | -7.76M | |||||
Income Tax Expense | 12K | 18K | 15K | 14K | 11K | |||||
Earnings From Continuing Operations | -24.77M | -3.61M | -16.74M | -7.64M | -7.77M | |||||
Net Income to Company | -24.77M | -3.61M | -16.74M | -7.64M | -7.77M | |||||
Net Income - (IS) | -24.77M | -3.61M | -16.74M | -7.64M | -7.77M | |||||
Net Income to Common Incl Extra Items | -24.77M | -3.61M | -16.74M | -7.64M | -7.77M | |||||
Net Income to Common Excl. Extra Items | -24.77M | -3.61M | -16.74M | -7.64M | -7.77M | |||||
Per Share Items | ||||||||||
Net EPS - Basic | -0.1 | -0.01 | -0.06 | -0.03 | -0.03 | |||||
Basic EPS - Continuing Operations | -0.1 | -0.01 | -0.06 | -0.03 | -0.03 | |||||
Basic Weighted Average Shares Outstanding | 240M | 266M | 270M | 277M | 285M | |||||
Net EPS - Diluted | -0.1 | -0.01 | -0.06 | -0.03 | -0.03 | |||||
Diluted EPS - Continuing Operations | -0.1 | -0.01 | -0.06 | -0.03 | -0.03 | |||||
Diluted Weighted Average Shares Outstanding | 240M | 266M | 270M | 277M | 285M | |||||
Normalized Basic EPS | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | |||||
Normalized Diluted EPS | -0.03 | -0.02 | -0.01 | -0.02 | -0.02 | |||||
Supplemental Items | ||||||||||
EBITDA | -15.52M | -10.96M | -4.82M | -4.25M | -4.48M | |||||
EBITA | -15.6M | -11.04M | -4.89M | -4.25M | -4.48M | |||||
EBIT | -15.94M | -11.43M | -5.18M | -4.6M | -4.91M | |||||
Effective Tax Rate - (Ratio) | -0.05 | -0.5 | -0.09 | -0.18 | -0.14 | |||||
Current Domestic Taxes | - | - | - | - | - | |||||
Total Current Taxes | 12K | 18K | 15K | 14K | 11K | |||||
Normalized Net Income | -7.5M | -6.05M | -3.93M | -4.44M | -5.79M | |||||
Interest on Long-Term Debt | 800K | 1.64M | - | - | - | |||||
Supplemental Operating Expense Items | ||||||||||
General and Administrative Expenses | - | - | - | 1.8M | 1.96M | |||||
Research And Development Expense From Footnotes | 4.62M | 5.62M | 3.25M | 2.86M | 3.15M | |||||
Stock-Based Comp., R&D Exp. (Total) | 783K | 705K | 340K | - | 40K | |||||
Stock-Based Comp., G&A Exp. (Total) | - | - | - | 304K | 428K | |||||
Stock-Based Comp., SG&A Exp. (Total) | 1.84M | 1.69M | 909K | - | - | |||||
Total Stock-Based Compensation | 2.62M | 2.39M | 1.25M | 304K | 468K |
- Stock Market
- Stocks
- RVX Stock
- RVXCF Stock
- Financials Resverlogix Corp.
- Income Statement
Select your edition
All financial news and data tailored to specific country editions
















